Business
Total Voting Rights Correction
Ondine Biomedical Inc. announced a correction to its total voting rights figure previously stated on August 28, 2025. Following Admission on September 3, 2025, the company's issued and fully paid share capital will consist of 518,366,964 Common Shares, which supersedes the previously announced figure of 517,566,964 Common Shares. Each share carries one voting right, and the company holds no Common Shares in treasury. Therefore, the total number of Common Shares and voting rights will be 518,366,964. This figure should be used by Existing Shareholders to determine if they are required to notify their interest in the Company. Disclaimer*
About this update from Ondine Biomedical, Inc.
1 September 2025 Ondine Biomedical Inc. ("Ondine" or the "Company") Total Voting Rights Correction Ondine Biomedical Inc. (AIM: OBI), a Canadian life sciences company, announces a correction to the total voting rights figure stated in the Company's announcement on 28 August 2025. Following Admission on 3 September 2025, the Company's issued and fully paid share capital will consist of 518,366,964 Common Shares, and not 517,566,964 Common Shares, as previously stated. Total Voting Rights Following Admission, the Company's issued and fully paid share capital will consist of 518,366,964 Common Shares, all of which carry one voting right per share. The Company does not hold any Common Shares in treasury. Therefore, the total number of Common Shares and voting rights in the Company at this date will be 518,366,964 Common Shares. This figure may be used from the date of Admission until further notice by Existing Shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules. Capitalized terms used in this announcement have the meanings given to them in the Company's announcements dated 27 August 2025 and 28 August 2025, unless the context provides otherwise. Enquiries: Ondine Biomedical Inc. www.ondinebio.com Carolyn Cross, CEO +1 604 669 0555 or via Vane Percy & Roberts Strand Hanson Limited (Nominated Adviser & Joint Financial Adviser) James Harris, Richard Johnson +44 (0)20 7409 3494 Peel Hunt LLP (Joint Bookrunner and Broker, Joint Financial Adviser) James Steel, Dr. Chris Golden +44 (0)20 7418 8900 Orana Corporate LLP (Joint Bookrunner and Broker to the Placing) Sebastian Wykeham +33 6 7120 1513 Vane Percy & Roberts (Media Contact) Simon Vane Percy +44 (0)77 1000 5910
View stock analysis, news, and events for Ondine Biomedical, Inc.